
|Articles|March 3, 2008
Post-marketing liver injury reports lead to Tysabri PI update
Liver injury warnings added to natalizumab prescribing information.
Advertisement
Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Bepirovirsen Meets Primary End Point for Functional Cure Rate of Hepatitis B
2
GoodRx Offers Wegovy Weight-Loss Pill at Under $150 a Month
3
The PBM Putting Pharmacists at the Center of Formulary Design
4
HHS Limits Vaccine Recommendations for Childhood Schedules
5










































































































































































































